Celltrion's Q2 Operating Profit Surges 77% to 430 Billion Won
Achieving Record-High Second-Quarter Results
On July 3, Celltrion announced that its consolidated provisional results for the second quarter of this year showed sales of 1.3 trillion won and an operating profit of 430 billion won.
Compared to the same period last year, sales increased by 35.2%, and operating profit rose by 77.3%. This is the largest second-quarter performance in the company's history. The operating margin also improved significantly, jumping from 25% last year to approximately 33%, achieving both external growth and profitability improvement.
Analysts note that these results are especially meaningful as they represent "qualitative growth"—not just an increase in sales, but also a higher proportion of high-margin new products and improvements in cost structure occurring simultaneously. Celltrion exceeded market expectations in the second quarter, following a strong first quarter, demonstrating that its business competitiveness is now being fully reflected in financial results. Furthermore, by surpassing its second-quarter operating profit target of 400 billion won, which was announced in the business and management plan disclosure at the beginning of the year, the company has further increased confidence in achieving its annual business plan.
Most notably, considering the biosimilar industry's characteristic seasonality—wherein sales expand in the second half of the year due to major national tender supplies and year-end inventory buildup—growth momentum is expected to accelerate even further in the second half. As a result, expectations are rising for the company to exceed its annual performance targets.
Transformation to a Growth Structure Centered on High-Margin New Products
This strong performance is the result of robust sales of existing core products, combined with the rapid growth of high-margin new products, leading to a reorganization of the product portfolio around high value-added offerings.
New products such as Remsima SC (marketed as Zymfentra in the U.S.), Yuflyma, and Stekyma have maintained strong growth in major global markets, with the share of new products in total sales now exceeding 60%. Zymfentra continues to break its own record for prescriptions in the U.S., while Stekyma is quickly increasing its share and has joined the leading group in the U.S. market. Aptozma and Stoboclo-Osenbelt have also successfully established themselves in the market and are becoming new growth drivers.
In Europe, Omliclo, as a first-mover, continues to benefit from its market leadership, while Vegzelma maintains the number one market share in key countries despite being a latecomer. Aptozma, Yuflyma, and Stoboclo-Osenbelt are also entering a phase of significant sales expansion and are expected to be important growth engines in the second half of the year.
Profitability is also being structurally improved. Most of the one-off costs that arose after the merger have been resolved, while the depletion of high-cost inventory, completion of development cost amortization, and improvements in production yield (Titer Improvement) have all contributed to ongoing enhancements in cost competitiveness. The company expects this profitability improvement to be sustainable, as it is based on structural changes such as product mix optimization and increased production efficiency, rather than one-off effects.
Simultaneous Strengthening of Biosimilars, New Drugs, and Production Capacity
In addition to current performance growth, Celltrion is accelerating efforts to secure future growth drivers. The Cosentyx biosimilar CT-P55 for autoimmune diseases is undergoing approval procedures in Korea, North America, and other key markets, and Herzuma SC is also steadily pursuing approval in major global countries. The development of follow-on biosimilars such as Keytruda and Darzalex is progressing smoothly, with Celltrion aiming to establish a portfolio of 30 biosimilars by 2030 and a total of 41 by 2038.
Aerial view of Celltrion Plant 2 in Songdo, Incheon. / Incheon – Photo by Hyunmin Kim kimhyun81@
View original imageNew drug development is also progressing well. CT-P70 and CT-P71 have received Fast Track designation from the U.S. Food and Drug Administration (FDA), accelerating their development. The company is continuing to expand its R&D investment with the goal of securing a portfolio of 20 new drugs by next year.
Efforts are also underway to expand production capacity to support the broader product portfolio. In Korea, alongside the existing 250,000-liter production facility, expansion of Plants 4 and 5 with a combined capacity of 180,000 liters is in progress. In the U.S., the Branchburg, New Jersey plant is set for a 75,000-liter expansion. Through these efforts, the company aims to secure a total production capacity of 141,000 liters in the U.S., thereby strengthening both global supply stability and responsiveness to the U.S. market.
In particular, the expansion of U.S. manufacturing facilities is expected to have a positive impact on long-term corporate value by structurally mitigating tariff and supply chain risks, while also laying the groundwork for the expansion of global contract manufacturing (CMO) business operations.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion official stated, "This performance demonstrates that our strategy of expanding new products and improving profitability is now delivering tangible results. By simultaneously expanding our product portfolio, strengthening production capacity, and developing new drugs, we are further reinforcing a foundation for sustainable growth. In the second half, as major national tenders and new product growth are expected to be fully reflected, we aim to achieve results that surpass the first half and continue to enhance our competitiveness as we strive to become a global big pharma."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.